NEW YORK, March 12, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting Medivation, Inc. (NASDAQ: MDVN), MannKind Corp. (NASDAQ: MNKD), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Charles River Laboratories International, Inc. (NYSE: CRL) and Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Medivation, Inc. Research Report
After the approval of XTANDI, a capsule treatment for patients with metastatic castration resistant prostate cancer, analysts already expected that it will boost Medivation's revenues for fourth quarter and year-end earnings for 2012. Medivation is pursuing the commercialization of XTANDI where medical need remains high. XTANDI has a lot of room growth as Medivation continues to penetrate new markets. The initial sales of XTANDI reached $71.5 million for full-year 2012. The Full Research Report on Medivation, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/67e4_MDVN]
--
MannKind Corp. Research Report
The growth potential of MannKind is a bullish story for analysts and investors as it offers therapeutic products for patients with diabetes and cancer. The markets for the treatment of these illnesses are among the biggest, and this serves as a market advantage for MannKind. The company reported at 25.2% increase in research and development as part of its commitment to develop and to commercialize breakthrough products. MannKind spent $25.3 million during the fourth quarter for clinical trial related activities. The Full Research Report on MannKind Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/f4b0_MNKD]
--
Questcor Pharmaceuticals, Inc. Research Report
Questcor's plan to acquire BioVectra Inc. is a step forward to stronger earnings as it is considered accretive to its financial results. As early as now, investors are expecting a better performance from Questcor after the company reported its fourth quarter and full-year 2012 earnings. Questcor's plan to ramp up its research and development serves as one of the best signals that have been causing steady inflows. The company's projects underway are for the treatment of lupus, idiopathic membranous nephropathy, diabetic nephropathy and amyotrophic lateral sclerosis (ALS). The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/21da_QCOR]
--
Charles River Laboratories International, Inc. Research Report
Since Charles River Laboratories acquired Accugenix, Inc. and majority ownership of Vital River, the company has been seeing a stock uptrend as a result of increased investments. Charles River Laboratories has been consistently finding ways to diversify its portfolio while it creates strategic partnership with other biotechnology players. The decision of AstraZeneca to partner with Charles River Laboratories is focused on outsourced regulated safety assessment and development drug metabolism and pharmacokinetics (DMPK). Recently, the company also announced that its instrumented colony for cerebrospinal dosing or CSF collection is already available. The Full Research Report on Charles River Laboratories International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/679a_CRL]
--
Peregrine Pharmaceuticals, Inc. Research Report
As a leader in first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, Peregrine Pharmaceuticals has been pursuing multiple clinical programs with lead product candidates bavituximab and Cotara. Peregrine Pharmaceutical's bavituximab is set to enter Phase III development after its 60% improvement in median overall survival in patients. Analysts are expecting the company to ramp up its research and development amid the optimism for its ongoing programs. Peregrine Pharmaceuticals is set to report its third quarter fiscal year 2013 financial results after market close on March 12, 2013. The Full Research Report on Peregrine Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/e4fd_PPHM]
--
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers
Email: press@investors-alliance.com
Main: +1-(480)-745-7826
SOURCE Investors-Alliance